Apollomics (APLM) Competitors $5.45 -0.46 (-7.78%) Closing price 08/15/2025 03:55 PM EasternExtended Trading$5.59 +0.14 (+2.57%) As of 08/15/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. BDRX, MIRA, NNVC, TENX, JATT, FBLG, LSTA, NAII, CASI, and RVPHShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Biodexa Pharmaceuticals (BDRX), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), Tenax Therapeutics (TENX), JATT Acquisition (JATT), FibroBiologics (FBLG), Lisata Therapeutics (LSTA), Natural Alternatives International (NAII), CASI Pharmaceuticals (CASI), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Its Competitors Biodexa Pharmaceuticals MIRA Pharmaceuticals NanoViricides Tenax Therapeutics JATT Acquisition FibroBiologics Lisata Therapeutics Natural Alternatives International CASI Pharmaceuticals Reviva Pharmaceuticals Biodexa Pharmaceuticals (NASDAQ:BDRX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Which has more volatility & risk, BDRX or APLM? Biodexa Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Which has better valuation and earnings, BDRX or APLM? Biodexa Pharmaceuticals has higher earnings, but lower revenue than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K9.29-$7.32MN/AN/AApollomics$1.49M4.02-$53.86MN/AN/A Do institutionals & insiders have more ownership in BDRX or APLM? 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to BDRX or APLM? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat Biodexa Pharmaceuticals' score of 1.43 indicating that Apollomics is being referred to more favorably in the news media. Company Overall Sentiment Biodexa Pharmaceuticals Positive Apollomics Very Positive Is BDRX or APLM more profitable? Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Apollomics N/A N/A N/A SummaryBiodexa Pharmaceuticals beats Apollomics on 5 of the 8 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.52M$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.11%P/E RatioN/A20.8931.0825.11Price / Sales4.02364.47466.21115.16Price / CashN/A42.3037.4059.05Price / Book1.228.659.096.18Net Income-$53.86M-$54.65M$3.26B$265.11M7 Day Performance-4.05%6.56%7.36%4.21%1 Month Performance-9.32%7.53%5.47%2.01%1 Year Performance-58.49%13.69%30.61%23.74% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics0.4362 of 5 stars$5.45-7.8%N/A-63.2%$6.52M$1.49M0.0045Positive NewsGap DownBDRXBiodexa Pharmaceuticals1.0285 of 5 stars$7.05+2.1%N/AN/A$25.55M$470K0.0020Short Interest ↓MIRAMIRA Pharmaceuticals3.2629 of 5 stars$1.46+2.8%$17.00+1,064.4%-20.2%$24.70MN/A-2.862Earnings ReportShort Interest ↓NNVCNanoViricides0.3133 of 5 stars$1.53-1.0%N/A-21.9%$24.51MN/A-2.1220TENXTenax Therapeutics1.9402 of 5 stars$5.87+0.3%$17.50+198.4%+49.3%$24.34MN/A-2.369News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionJATTJATT AcquisitionN/A$1.41-0.7%N/A-47.1%$24.32MN/A0.003High Trading VolumeFBLGFibroBiologics3.2291 of 5 stars$0.58+3.7%$13.00+2,160.9%-52.2%$23.96MN/A-1.5910Short Interest ↑LSTALisata Therapeutics2.2822 of 5 stars$2.67-3.8%$23.50+781.8%-12.5%$23.35M$1M-1.2030Short Interest ↑Analyst RevisionNAIINatural Alternatives International1.5437 of 5 stars$3.74+1.1%N/A-29.5%$23.12M$113.80M-2.69290Positive NewsCASICASI Pharmaceuticals4.0839 of 5 stars$1.84+6.1%$4.00+118.0%-63.7%$22.76M$28.54M-0.73180RVPHReviva Pharmaceuticals2.9482 of 5 stars$0.46+2.3%$9.00+1,865.1%-21.2%$22.13MN/A-0.585News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap Up Related Companies and Tools Related Companies Biodexa Pharmaceuticals Competitors MIRA Pharmaceuticals Competitors NanoViricides Competitors Tenax Therapeutics Competitors JATT Acquisition Competitors FibroBiologics Competitors Lisata Therapeutics Competitors Natural Alternatives International Competitors CASI Pharmaceuticals Competitors Reviva Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredThe Debt Crisis Is Coming—Will You Be Ready?A full-blown "economic heart attack" is coming—and the markets aren't ready. The problem? Exploding U.S. de...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access